pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Nexplanon
drug
save

etonogestrel CR

Marketedupdated 3mo ago
by $DARE Dare Bioscience, Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • drugIMPLANON39 co-mentions · 20 sources
  • tagApproval38 co-mentions · 19 sources
  • drugetonogestrel ER20 co-mentions · 20 sources
  • drugetonogestrel LA20 co-mentions · 20 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for contraception and 7 investigational indications.

all catalysts(19)

approval · 19
Jul 17, 2006
approval
$OGN13.74+0.07%
20y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Jan 18, 2007
approval
$OGN13.74+0.07%
20y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Feb 19, 2009
approval
$OGN13.74+0.07%
18y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
May 13, 2011
approval
$OGN13.74+0.07%
15y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Feb 1, 2012
approval
$OGN13.74+0.07%
15y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Jun 12, 2013
approval
$OGN13.74+0.07%
13y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Sep 27, 2013
approval
$OGN13.74+0.07%
13y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Jul 3, 2014
approval
$OGN13.74+0.07%
12y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Aug 19, 2015
approval
$OGN13.74+0.07%
11y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Sep 3, 2015
approval
$OGN13.74+0.07%
11y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Mar 14, 2016
approval
$OGN13.74+0.07%
10y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
May 19, 2017
approval
$OGN13.74+0.07%
9y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Apr 22, 2019
approval
$OGN13.74+0.07%
7y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Sep 24, 2020
approval
$OGN13.74+0.07%
6y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Sep 24, 2020
approval
$OGN13.74+0.07%
6y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Sep 29, 2023
approval
$OGN13.74+0.07%
3y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Sep 29, 2023
approval
$OGN13.74+0.07%
3y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Sep 29, 2023
approval
$OGN13.74+0.07%
3y ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
Jan 16, 2026
approval
$OGN13.74+0.07%
7mo ago
IMPLANON (ETONOGESTREL) — FDA approval
etonogestrel CR
→
view all 19 catalysts →

Trials studying etonogestrel CR

  • phase2An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)completedn=84
  • phase2A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)terminatedn=16
  • phase3A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)completedn=498
  • EP1Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrelsuspendedn=40
  • phase4Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africacompletedn=110
  • phase2A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)completedn=666
  • phase2A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)completedn=439
  • phase3Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)terminatedn=25
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 28, 2026
7 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

  • Jul 28, 2030formulationUS 97575523.9y
  • Jul 28, 2030formulationUS 97575523.9y
  • Sep 28, 2027formulationUS 87220371.1y
  • May 31, 2027formulationUS 10821277283d
  • Aug 28, 2026formulationUS 88887457d

FDA exclusivities (1)

  • Jan 16, 2029D-199New Indication (3y)2.4y

News(0)

no news has mentioned this drug yet

brand
Nexplanon
generic
etonogestrel
MOA
Progesterone receptor agonist
indication
Female Contraception
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 23m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?